Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa

Stuart H Isaacson, Julia Skettini, Stuart H Isaacson, Julia Skettini

Abstract

Neurogenic orthostatic hypotension (nOH) is due to failure of the autonomic nervous system to regulate blood pressure in response to postural changes due to an inadequate release of norepinephrine, leading to orthostatic hypotension and supine hypertension. nOH is common in Parkinson's disease (PD). Prevalence varies throughout the course of PD, ranging from 40% to 60%, and resulting in symptomatic nOH in approximately half. Symptomatic nOH, including lightheadedness, can limit daily activities and lead to falls. Symptomatic nOH can also limit therapeutic options for treating PD motor symptoms. Clinical evaluation should routinely include symptom assessment and blood pressure measurement of supine, sitting, and 3-minute standing; 24-hour ambulatory blood pressure monitoring can also be helpful. Non-pharmacological management of symptomatic nOH involves education, physical maneuvers, and adequate hydration. Current pharmacological treatment of symptomatic nOH includes salt supplement, fludrocortisone, midodrine, pyridostigmine, and other empiric medications. Despite these options, treatment of symptomatic nOH remains suboptimal, often limited by severe increases in supine blood pressure. Droxidopa, an oral prodrug converted by decarboxylation to norepinephrine, is a promising therapeutic option for symptomatic nOH in PD, improving symptoms of nOH, daily activities, falls, and standing systolic blood pressure in several recent trials. These trials demonstrated short-term efficacy and tolerability, with comparable increases in standing and supine blood pressures. Longer-term studies are ongoing to confirm durability of treatment effect.

Keywords: (pre)syncope; autonomic; falls; lightheadedness; norepinephrine; treatment.

Figures

Figure 1
Figure 1
Overlapping causes of symptomatic nOH (Venn diagram): 1) autonomic failure of NE pathways upon standing; 2) dopaminergic and other medications causing lower SBP; and 3) suboptimal hydration leading to reduced circulating blood volume. Note: *Medications include dopaminergic, diuretics, central adrenergic inhibitors, alpha-1 antagonists, nitrates. Abbreviations: nOH, neurogenic orthostatic hypotension; SBP, systolic blood pressure; s-SBP, standing SBP.
Figure 2
Figure 2
Treatment goals for patients with symptomatic nOH. Abbreviations: nOH, neurogenic orthostatic hypotension; s-SBP, standing systolic blood pressure.
Figure 3
Figure 3
Management of symptomatic nOH. Abbreviations: nOH, neurogenic orthostatic hypotension; s-SBP, standing systolic blood pressure.

References

    1. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–589.
    1. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(10):1470–1471.
    1. Sithinamsuwan P, Orrawanhanothai P, Thithum K, et al. Orthostatic hypotension: a non-motor complication assessment in 82 patients with idiopathic Parkinson’s disease in Phramongkutklao Hospital. J Med Assoc Thai. 2010;93(Suppl 6):S93–S99.
    1. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis. 2012;46(3):572–580.
    1. Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625–628.
    1. Mathias CJ. To stand on one’s own legs. Clin Med. 2002;2(3):237–245.
    1. Sharabi Y, Imrich R, Holmes C, Pechnik S, Goldstein DS. Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson’s disease with orthostatic hypotension. Mov Disord. 2008;23(12):1725–1732.
    1. Schatz IJ. Orthostatic hypotension. I. Functional and neurogenic causes. Arch Intern Med. 1984;144(4):773–777.
    1. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72.
    1. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615–624.
    1. Senard JM, Pathak A. Neurogenic orthostatic hypotension of Parkinson’s disease: what exploration for what treatment? Rev Neurol (Paris) 2010;166(10):779–784.
    1. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139–146.
    1. Goodall MC, Harlan WR, Jr, Alton H. Decreased noradrenaline (norepinephrine) synthesis in neurogenic orthostatic hypotension. Circulation. 1968;38(3):592–603.
    1. Goldstein DS, Polinsky RJ, Garty M, et al. Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol. 1989;26(4):558–563.
    1. Imrich R, Eldadah BA, Bentho O, et al. Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism Relat Disord. 2009;15(2):122–127.
    1. Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci. 2011;310(1–2):123–128.
    1. Bonuccelli U, Lucetti C, Del Dotto P, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60(10):1400–1404.
    1. Milazzo V, Di Stefano C, Servo S, Zibetti M, Lopiano L, Maule S. Neurogenic orthostatic hypotension as the initial feature of Parkinson disease. Clin Auton Res. 2012;22(4):203–206.
    1. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology. 2004;63(6):1093–1095.
    1. Oka H, Toyoda C, Yogo M, Mochio S. Cardiovascular dysautonomia in de novo Parkinson’s disease without orthostatic hypotension. Eur J Neurol. 2011;18(2):286–292.
    1. Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology. 2003;60(8):1327–1332.
    1. Goldstein DS, Holmes C, Patronas N, Kopin IJ. Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension. Clin Sci (Lond) 2003;104(6):649–654.
    1. Schatz IJ. Orthostatic hypotension. II. Clinical diagnosis, testing, and treatment. Arch Intern Med. 1984;144(5):1037–1041.
    1. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7(5):451–458.
    1. Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):74–80.
    1. Omboni S, Smit AA, van Lieshout JJ, Settels JJ, Langewouters GJ, Wieling W. Mechanisms underlying the impairment in orthostatic tolerance after nocturnal recumbency in patients with autonomic failure. Clin Sci (Lond) 2001;101(6):609–618.
    1. Lipsitz LA, Ryan SM, Parker JA, Freeman R, Wei JY, Goldberger AL. Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. Circulation. 1993;87(2):391–400.
    1. Lipsitz LA, Pluchino FC, Wei JY, Minaker KL, Rowe JW. Cardiovascular and norepinephrine responses after meal consumption in elderly (older than 75 years) persons with postprandial hypotension and syncope. Am J Cardiol. 1986;58(9):810–815.
    1. Pathak A, Lapeyre-Mestre M, Montastruc JL, Senard JM. Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov Disord. 2005;20(9):1213–1219.
    1. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging. 2001;18(7):495–505.
    1. Meco G, Pratesi L, Bonifati V. Cardiovascular reflexes and autonomic dysfunction in Parkinson’s disease. J Neurol. 1991;238(4):195–199.
    1. Lang AE. Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy. Arch Neurol. 2001;58(5):835.
    1. Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295–310.
    1. Jamnadas-Khoda J, Koshy S, Mathias CJ, Muthane UB, Ragothaman M, Dodaballapur SK. Are current recommendations to diagnose orthostatic hypotension in Parkinson’s disease satisfactory? Mov Disord. 2009;24(12):1747–1751.
    1. Stuebner E, Vichayanrat E, Low DA, Mathias CJ, Isenmann S, Haensch CA. Twenty-four hour non-invasive ambulatory blood pressure and heart rate monitoring in Parkinson’s disease. Front Neurol. 2013;4:49.
    1. Poda R, Guaraldi P, Solieri L, et al. Standing worsens cognitive functions in patients with neurogenic orthostatic hypotension. Neurol Sci. 2012;33(2):469–473.
    1. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79–90.
    1. Hillen ME, Wagner ML, Sage JI. “Subclinical” orthostatic hypotension is associated with dizziness in elderly patients with Parkinson disease. Arch Phys Med Rehabil. 1996;77(7):710–712.
    1. Camilleri M, Malagelada JR, Stanghellini V, Fealey RD, Sheps SG. Gastrointestinal motility disturbances in patients with orthostatic hypotension. Gastroenterology. 1985;88(6):1852–1859.
    1. Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson’s disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci. 2012;313(1–2):57–63.
    1. Kopin IJ, Polinsky RJ, Oliver JA, Oddershede IR, Ebert MH. Urinary catecholamine metabolites distinguish different types of sympathetic neuronal dysfunction in patients with orthostatic hypotension. J Clin Endocrinol Metab. 1983;57(3):632–637.
    1. Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1–8.
    1. Gurevich TY, Groozman GB, Giladi N, Drory VE, Hausdorff JM, Korczyn AD. R-R interval variation in Parkinson’s disease and multiple system atrophy. Acta Neurol Scand. 2004;109(4):276–279.
    1. Haensch CA, Lerch H, Jorg J, Isenmann S. Cardiac denervation occurs inde-pendent of orthostatic hypotension and impaired heart rate variability in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(2):134–137.
    1. Smit AA, Wieling W, Opfer-Gehrking TL, van Emmerik-Levelt HM, Low PA. Patients’ choice of portable folding chairs to reduce symptoms of orthostatic hypotension. Clin Auton Res. 1999;9(6):341–344.
    1. Jordan J, Shannon JR, Black BK, et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation. 2000;101(5):504–509.
    1. Z’Graggen WJ, Hess CW, Humm AM. Acute fluid ingestion in the treatment of orthostatic intolerance – important implications for daily practice. Eur J Neurol. 2010;17(11):1370–1376.
    1. Bouvette CM, McPhee BR, Opfer-Gehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc. 1996;71(9):847–853.
    1. Smit AA, Wieling W, Fujimura J, et al. Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res. 2004;14(3):167–175.
    1. Podoleanu C, Maggi R, Brignole M, et al. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol. 2006;48(7):1425–1432.
    1. van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res. 2000;10(1):35–42.
    1. Hickler RB, Thompson GR, Fox LM, Hamlin JT., 3rd Successful treatment of orthostatic hypotension with 9-alpha-fluorohydrocortisone. N Engl J Med. 1959;261:788–791.
    1. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–124.
    1. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.
    1. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–1051.
    1. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513–518.
    1. Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res. 1995;5(4):211–213.
    1. Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med. 1993;329(9):611–615.
    1. Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986;293(6543):353–354.
    1. Abate G, Polimeni RM, Cuccurullo F, Puddu P, Lenzi S. Effects of indomethacin on postural hypotension in Parkinsonism. Br Med J. 1979;2(6203):1466–1468.
    1. Onrot J, Goldberg MR, Biaggioni I, Hollister AS, Kingaid D, Robertson D. Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med. 1985;313(9):549–554.
    1. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–936.
    1. Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987;37(2):215–220.
    1. Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604–610.
    1. Okamoto LE, Shibao C, Gamboa A, et al. Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension. 2012;59(3):650–656.
    1. Freeman R, Landsberg L. The treatment of orthostatic hypotension with dihydroxyphenylserine. Clin Neuropharmacol. 1991;14(4):296–304.
    1. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–728.
    1. Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006;24(3–4):189–203.
    1. Kaufmann H. Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson’s disease? Neurology. 1996;47(6):1370–1371.
    1. Narabayashi H, Nakanishi T. Therapeutic effects of L-DOPS in Parkinson’s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy. Clin Eval. 1987;15:423–457.
    1. Yanagisawa N, Ikeda S, Hashimoto T, et al. Effects of L-threo-Dops on orthostatic hypotension in Parkinson’s disease. No To Shinkei. 1998;50(2):157–163. Japanese.
    1. Mathias CJ, Senard JM, Cortelli P. A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy and Parkinson’s disease. Clin Auton Res. 2007;17:272.
    1. Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004;14(6):363–368.
    1. Kaufmann H, Mathias C, Freeman R, Low P, Biaggioni I, Droxidopa Study Group Treatment with droxidopa – a phase III multinational, placebo-controlled, parallel group, withdrawal-design study in subjects with neurogenic orthostatic hypotension and non-diabetic autonomic neuropathy. Clin Auton Res. 2009;19:281.
    1. Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt A, Mathias C. Treatment of neurogenic orthostatic hypotension: results from a multi-center, double-blind, randomized, placebo-controlled, parallel group, induction design study. Neurology. 2012;78:PL02.001.
    1. Isaacson S, Shill H, Vernino S, Cioffi C, Hutchman R. Durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH 303) Mov Disord. 2012;27:S424–S425.
    1. Kaufmann H, Klos K, Hutchman R, Isaacson S. Effects of droxidopa (Northera™) on 24 hour blood pressure (BP) in patients with symptomatic neurogenic orthostatic hypotension (NOH) Mov Disord. 2010;25:S405–S406.
    1. Shill H, Vernino S, Hutchman R, Adkins L, Isaacson S. A multicenter, open-label study to assess the long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension (NOH 304) Mov Disord. 2012;27:S428.
    1. Isaacson SH, Hauser RA, Szakacs CBN, Cioffi CC. Droxidopa treatment impact on orthostatic symptoms and standing systolic blood pressure in patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension: Study 306. Neurology. 2013;80 Emerging Science Abstract 010.
    1. Isaacson S, Hauser RA, Szakacs CBN, Cioffi CC. Impact of droxidopa treatment in patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension (study 306) Mov Disord. 2013;28(Suppl 1):468.
    1. Hauser RA, Schwieterman W, Isaacson S. Impact of treatment with droxidopa in repeat fallers with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension (NOH 306A) Mov Disord. 2012;27:S423.
    1. Biaggioni I, Low P, Rowse G, Kaufmann H. Analysis of efficacy in patients with symptomatic neurogenic orthostatic hypotension treated with droxidopa and dopa-decarboxylase inhibitors. Mov Disord. 2012;27:S422–S423.
    1. LeWitt P, Gorny S. Analysis of efficacy and safety outcomes in patients treated with droxidopa in combination with other drug classes. Mov Disord. 2012;27:S425–S426.
    1. Low P, Nelson J, Stacy M. Safety and efficacy of droxidopa in patients previously treated with midodrine. Mov Disord. 2012;27:S426.
    1. Mathias C, Low P, Freeman R, Hewitt L, Kaufmann H. Integrated efficacy analysis of droxidopa in 2 double-blind, placebo-controlled Phase 3 studies in patients with neurogenic orthostatic hypotension. Mov Disord. 2012;27:S426.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren